Novartis AG Company Profile (NYSE:NVS)

About Novartis AG (NYSE:NVS)

Novartis AG logoNovartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NYSE:NVS
  • CUSIP: N/A
  • Web: www.novartis.com
Capitalization:
  • Market Cap: $202.36 billion
  • Outstanding Shares: 2,616,845,000
Average Prices:
  • 50 Day Moving Avg: $85.27
  • 200 Day Moving Avg: $81.90
  • 52 Week Range: $66.93 - $86.90
P/E:
  • Trailing P/E Ratio: 31.45
  • Foreward P/E Ratio: 16.55
  • P/E Growth: 3.23
Sales & Book Value:
  • Annual Revenue: $49.18 billion
  • Price / Sales: 4.60
  • Book Value: $29.84 per share
  • Price / Book: 2.89
Dividend:
  • Annual Dividend: $2.30
  • Dividend Yield: 3.2%
Profitability:
  • EBITDA: $14.46 billion
  • Net Margins: 13.52%
  • Return on Equity: 15.51%
  • Return on Assets: 8.41%
Debt:
  • Debt-to-Equity Ratio: 0.33%
  • Current Ratio: 1.01%
  • Quick Ratio: 0.75%
Misc:
  • Average Volume: 1.57 million shs.
  • Beta: 0.73
  • Short Ratio: 1.69
 

Frequently Asked Questions for Novartis AG (NYSE:NVS)

What is Novartis AG's stock symbol?

Novartis AG trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

How often does Novartis AG pay dividends? What is the dividend yield for Novartis AG?

Novartis AG declared an annual dividend on Friday, January 27th. Shareholders of record on Friday, March 3rd will be given a dividend of $2.327 per share on Friday, March 3rd. The ex-dividend date of this dividend is Wednesday, March 1st. View Novartis AG's Dividend History.

How will Novartis AG's stock buyback program work?

Novartis AG declared that its Board of Directors has authorized a stock buyback program on Saturday, April 8th 2017, which authorizes the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 2.9% of its stock through open market purchases. Stock buyback programs are often an indication that the company's management believes its shares are undervalued.

How were Novartis AG's earnings last quarter?

Novartis AG (NYSE:NVS) announced its earnings results on Tuesday, July, 18th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.06. The firm earned $12.24 billion during the quarter, compared to the consensus estimate of $12.20 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. Novartis AG's revenue was down 1.8% on a year-over-year basis. During the same period in the previous year, the company posted $1.23 EPS. View Novartis AG's Earnings History.

When will Novartis AG make its next earnings announcement?

Novartis AG is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Novartis AG.

Where is Novartis AG's stock going? Where will Novartis AG's stock price be in 2017?

14 equities research analysts have issued 12-month price objectives for Novartis AG's stock. Their forecasts range from $74.37 to $90.00. On average, they anticipate Novartis AG's stock price to reach $82.92 in the next twelve months. View Analyst Ratings for Novartis AG.

Are investors shorting Novartis AG?

Novartis AG saw a decline in short interest in the month of September. As of September 15th, there was short interest totalling 1,327,917 shares, a decline of 33.5% from the August 31st total of 1,996,918 shares. Based on an average daily trading volume, of 1,788,278 shares, the days-to-cover ratio is presently 0.7 days.

Who are some of Novartis AG's key competitors?

Who are Novartis AG's key executives?

Novartis AG's management team includes the folowing people:

  • Joseph S. Jimenez, Chief Executive Officer, Member of the Executive Committee
  • Harry Kirsch, Chief Financial Officer, Member of the Executive Committee
  • Michael Ball, Chief Executive Officer of Alcon, Member of the Executive Committee
  • James Bradner M.D., President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee
  • Richard D. Francis, Chief Executive Officer of Sandoz Division, Member of the Executive Committee
  • Paul Hudson, Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee
  • Bruno Strigini, Chief Executive Officer of Novartis Oncology, Member of the Executive Committee
  • Felix R. Ehrat Ph.D., Group General Counsel, Member of the Executive Committee
  • Steven Baert, Head of Human Resources, Member of the Executive Committee
  • Vasant Narasimhan M.D., Chief Executive Officer, Member of the Executive Committee

Who owns Novartis AG stock?

Novartis AG's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Park National Corp OH (0.01%), Osborn Williams & Donohoe LLC (0.00%), Beacon Financial Group (0.00%), Eqis Capital Management Inc. (0.00%) and Private Asset Management Inc. (0.00%). Company insiders that own Novartis AG stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Institutional Ownership Trends for Novartis AG.

Who sold Novartis AG stock? Who is selling Novartis AG stock?

Novartis AG's stock was sold by a variety of institutional investors in the last quarter, including Private Asset Management Inc. and Osborn Williams & Donohoe LLC. View Insider Buying and Selling for Novartis AG.

Who bought Novartis AG stock? Who is buying Novartis AG stock?

Novartis AG's stock was acquired by a variety of institutional investors in the last quarter, including Park National Corp OH, Beacon Financial Group and Eqis Capital Management Inc.. Company insiders that have bought Novartis AG stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Insider Buying and Selling for Novartis AG.

How do I buy Novartis AG stock?

Shares of Novartis AG can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novartis AG's stock price today?

One share of Novartis AG stock can currently be purchased for approximately $86.37.


MarketBeat Community Rating for Novartis AG (NYSE NVS)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  271 (Vote Outperform)
Underperform Votes:  320 (Vote Underperform)
Total Votes:  591
MarketBeat's community ratings are surveys of what our community members think about Novartis AG and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Novartis AG (NYSE:NVS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 7 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.21)
Consensus Price Target: $82.92 (3.99% downside)
Consensus Price Target History for Novartis AG (NYSE:NVS)
Price Target History for Novartis AG (NYSE:NVS)
Analysts' Ratings History for Novartis AG (NYSE:NVS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/10/2017J P Morgan Chase & CoReiterated RatingNeutralN/AView Rating Details
8/9/2017Cowen and CompanySet Price TargetHold$90.00MediumView Rating Details
7/26/2017Morgan StanleyUpgradeUnderweight -> OverweightLowView Rating Details
7/5/2017Credit Suisse GroupDowngradeNeutral -> Underperform$82.25MediumView Rating Details
6/22/2017Leerink SwannReiterated RatingMarket Perform$83.00LowView Rating Details
6/22/2017Barclays PLCUpgradeUnderweight -> Equal WeightLowView Rating Details
3/22/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutralLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageBuy -> BuyLowView Rating Details
3/7/2017Societe GeneraleUpgradeHold -> Buy$73.82 -> $74.37N/AView Rating Details
3/7/2017BNP ParibasDowngradeNeutral -> UnderperformN/AView Rating Details
1/31/2017ArgusUpgradeHold -> BuyN/AView Rating Details
1/17/2017Berenberg BankDowngradeBuy -> HoldN/AView Rating Details
1/9/2017Deutsche Bank AGReiterated RatingNeutralN/AView Rating Details
10/16/2016Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
10/10/2016Chardan CapitalLower Price TargetBuy$95.00 -> $92.00N/AView Rating Details
7/12/2016Bank of America CorpReiterated RatingHoldN/AView Rating Details
5/24/2016Citigroup Inc.Reiterated RatingNeutralN/AView Rating Details
11/23/2015VontobelDowngradeHoldN/AView Rating Details
10/28/2015Sanford C. BernsteinLower Price TargetOutperform$102.00N/AView Rating Details
10/28/2015Main First Bank AGDowngradeUnderperformN/AView Rating Details
(Data available from 10/16/2015 forward)

Earnings

Earnings History for Novartis AG (NYSE:NVS)
Earnings by Quarter for Novartis AG (NYSE:NVS)
Earnings History by Quarter for Novartis AG (NYSE NVS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2017$1.25N/AView Earnings Details
7/18/2017Q2 17$1.16$1.22$12.20 billion$12.24 billionViewN/AView Earnings Details
4/25/20173/31/2017$1.10$1.13$11.59 billion$11.54 billionViewN/AView Earnings Details
1/25/2017Q416$1.12$1.12$12.44 billion$12.32 billionViewN/AView Earnings Details
10/25/2016Q316$1.19$1.23$12.24 billion$12.13 billionViewListenView Earnings Details
7/19/2016Q216$1.18$1.23$12.33 billion$12.47 billionViewListenView Earnings Details
4/21/2016Q116$1.18$1.17$11.90 billion$11.60 billionViewListenView Earnings Details
1/27/2016Q415$1.18$1.14$12.64 billion$12.52 billionViewListenView Earnings Details
10/27/2015Q315$1.31$1.27$12.66 billion$12.30 billionViewListenView Earnings Details
7/21/2015Q215$1.20$1.27$12.45 billion$12.70 billionViewListenView Earnings Details
4/23/2015Q115$1.12$1.33$12.90 million$11.94 billionViewN/AView Earnings Details
1/27/2015Q314$1.13$1.21$14.68 billion$14.63 billionViewN/AView Earnings Details
7/17/2014Q214$1.36$1.36$14.83 billion$14.64 billionViewN/AView Earnings Details
4/24/2014Q1 2014$1.33$1.31$14.25 billion$14.02 billionViewN/AView Earnings Details
1/29/2014Q413$1.27$1.20$15.16 billion$15.08 billionViewN/AView Earnings Details
10/22/2013Q313$1.31$1.26$14.28 billion$14.34 billionViewN/AView Earnings Details
7/17/2013Q213$1.29$1.30$14.39 billion$14.50 billionViewN/AView Earnings Details
4/24/2013Q113$1.28$1.32$14.02 million$14.02 billionViewN/AView Earnings Details
1/23/2013Q412$1.19$1.27$14.42 billion$14.80 billionViewN/AView Earnings Details
10/25/2012$1.34$1.34ViewN/AView Earnings Details
7/19/2012$1.33$1.38ViewN/AView Earnings Details
4/24/2012$1.30$1.27ViewN/AView Earnings Details
1/25/2012$1.26$1.23ViewN/AView Earnings Details
10/25/2011$1.45$1.45ViewN/AView Earnings Details
7/19/2011$1.46$1.48ViewN/AView Earnings Details
4/19/2011$1.30$1.41ViewN/AView Earnings Details
1/27/2011$1.25$1.14ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Novartis AG (NYSE:NVS)
2017 EPS Consensus Estimate: $4.75
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$1.08$1.15$1.12
Q2 20172$1.15$1.22$1.19
Q3 20172$1.24$1.25$1.25
Q4 20171$1.20$1.20$1.20
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Novartis AG (NYSE:NVS)
Most Recent Dividend:3/3/2017
Annual Dividend:$2.30
Dividend Yield:2.66%
Dividend Growth:3.90% (3 Year Average)
Payout Ratio:83.94% (Trailing 12 Months of Earnings)
48.42% (Based on This Year's Estimates)
44.06% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Novartis AG (NYSE:NVS)

Dividend History by Quarter for Novartis AG (NYSE NVS)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/27/2017Annual$2.333/1/20173/3/20173/3/2017
2/1/2016Annual$2.342/24/20162/26/20162/26/2016
2/4/2014annual$2.723.48%2/27/20143/3/20143/11/2014
2/11/2013annual$2.533.71%2/26/20132/28/20134/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Novartis AG (NYSE:NVS)
Insider Ownership Percentage: 0.01%
Institutional Ownership Percentage: 10.93%
Insider Trades by Quarter for Novartis AG (NYSE:NVS)
Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)
Insider Trades by Quarter for Novartis AG (NYSE:NVS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/5/2017Bioventures Ltd NovartisMajor ShareholderBuy266,667$15.00$4,000,005.00View SEC Filing  
5/11/2016Institutes For Biomed NovartisMajor ShareholderBuy277,777$18.00$4,999,986.00View SEC Filing  
2/17/2016Bioventures Ltd NovartisMajor ShareholderBuy375,000$8.00$3,000,000.00View SEC Filing  
9/22/2014Bioventures Ltd NovartisMajor ShareholderBuy325,000$15.00$4,875,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Novartis AG (NYSE:NVS)
Latest Headlines for Novartis AG (NYSE:NVS)
Source:
DateHeadline
thestreet.com logoFDA Advisory Committee Greenlights First Gene Therapy for Inherited Disorder
www.thestreet.com - October 13 at 7:36 AM
americanbankingnews.com logoNovartis AG (NVS) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - October 12 at 6:56 PM
finance.yahoo.com logoLilly's (LLY) Verzenio Fails in Phase III Lung Cancer Study
finance.yahoo.com - October 12 at 7:43 AM
finance.yahoo.com logoHere Come More Gene Therapies -- And More Pricing Debates
finance.yahoo.com - October 12 at 7:42 AM
finance.yahoo.com logoNovartis decides not to sell Roche stake chairman tells newspaper
finance.yahoo.com - October 12 at 7:42 AM
americanbankingnews.com logoNovartis AG (NVS) Earns Neutral Rating from J P Morgan Chase & Co
www.americanbankingnews.com - October 10 at 6:20 AM
zacks.com logoRoche (RHHBY) Receives FDA Approval For Cobas Zika Test
www.zacks.com - October 9 at 3:58 PM
nasdaq.com logoNovartis: Alcon Gets European CE Mark For Clareon IOL With AutonoMe
www.nasdaq.com - October 8 at 12:59 AM
investorplace.com logoNovartis AG’s (NVS) Hold Rating Affirmed
investorplace.com - October 8 at 12:59 AM
americanbankingnews.com logoFY2018 EPS Estimates for Novartis AG Decreased by Jefferies Group (NVS)
www.americanbankingnews.com - October 6 at 12:56 PM
americanbankingnews.com logoNovartis AG (NVS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - October 6 at 12:28 PM
investorplace.com logoNovartis AG's (NVS) Hold Rating Affirmed - Investorplace.com
www.investorplace.com - October 6 at 10:03 AM
investorplace.com logoNovartis AG’s (NVS) Hold Rating Affirmed
investorplace.com - October 6 at 9:54 AM
finance.yahoo.com logoTeva Down as Mylan's Copaxone 40 mg Generic Arrives Early
finance.yahoo.com - October 5 at 12:50 PM
finance.yahoo.com logoIIROC Trade Resumption - NVS
finance.yahoo.com - October 5 at 12:50 PM
finance.yahoo.com logoChanges in GlaxoSmithKline’s Valuation
finance.yahoo.com - October 5 at 12:50 PM
americanbankingnews.com logoNovartis AG (NVS) to Post Q3 2017 Earnings of $1.24 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - October 5 at 6:02 AM
americanbankingnews.com logoNovartis AG (NVS) Short Interest Down 33.5% in September
www.americanbankingnews.com - October 4 at 3:02 AM
zacks.com logoFDA Accepts Roche's (RHHBY) Application for Adjuvant Perjeta
www.zacks.com - October 3 at 8:40 AM
bizjournals.com logoDrug Makers Stocks on Investors' Radar -- Impax Laboratories, GlaxoSmithKline, Novartis, and TherapeuticsMD
www.bizjournals.com - October 3 at 8:40 AM
finance.yahoo.com logoTraining cells to fight cancer
finance.yahoo.com - October 2 at 7:20 PM
finance.yahoo.com logo[$$] Lilly Faces Off With Pfizer, Novartis
finance.yahoo.com - October 2 at 7:20 PM
zacks.com logoLigand's Captisol Deals Set to Drive Growth in the Long Run
www.zacks.com - September 29 at 12:58 PM
bizjournals.com logoUC Berkeley deal showcases Novartis' new focus on academic tie-ups
www.bizjournals.com - September 28 at 7:16 PM
americanbankingnews.com logoJ P Morgan Chase & Co Reaffirms Neutral Rating for Novartis AG (NVS)
www.americanbankingnews.com - September 26 at 11:50 AM
finanznachrichten.de logoPro-Trader Daily: Corporate News Blog - Novartis Receives EC's Approval for Rydapt; Set to Treat FLT3-Mutated Active Myeloid Leukemia
www.finanznachrichten.de - September 22 at 11:59 AM
finance.yahoo.com logoHow Did Novartis’s Established Medicines Perform in 1H17?
finance.yahoo.com - September 22 at 11:59 AM
finance.yahoo.com logoCorporate News Blog - Novartis Receives EC’s Approval for Rydapt; Set to Treat FLT3-Mutated Active Myeloid Leukemia
finance.yahoo.com - September 22 at 11:59 AM
finance.yahoo.com logo[$$] Alnylam's New Medicine To Enter Pricing Debate
finance.yahoo.com - September 22 at 11:59 AM
finance.yahoo.com logoGilenya and Entresto Could Keep Boosting Novartis’s Revenue Growth
finance.yahoo.com - September 22 at 11:59 AM
finance.yahoo.com logoAn Update on Novartis’s Sandostatin, Afinitor, and Exjade
finance.yahoo.com - September 20 at 7:06 AM
finanznachrichten.de logoNovartis: Xolair Confirms Re-treatment Efficacy In CSU Patients
www.finanznachrichten.de - September 19 at 5:54 AM
seekingalpha.com logoNovartis: The Value Creator
seekingalpha.com - September 19 at 5:54 AM
finance.yahoo.com logoHow Is Novartis’s Lucentis Positioned after 1H17?
finance.yahoo.com - September 19 at 5:54 AM
finance.yahoo.com logoHow Did Novartis Perform in 1H17?
finance.yahoo.com - September 19 at 5:54 AM
finance.yahoo.com logoKisqali Could Significantly Boost Novartis’s Revenue Growth
finance.yahoo.com - September 19 at 5:54 AM
finance.yahoo.com logoNovartis Announces Positive Data on Urticaria Drug Xolair
finance.yahoo.com - September 19 at 5:54 AM
americanbankingnews.com logoNovartis AG (NVS) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 17 at 5:08 PM
finance.yahoo.com logoNovartis Sees IBD RS Rating Rise To 72
finance.yahoo.com - September 17 at 6:18 AM
finance.yahoo.com logoNovartis Sees IBD RS Rating Rise To 72
finance.yahoo.com - September 17 at 6:18 AM
finanznachrichten.de logoTransCelerate BioPharma Adds Novartis; Elects Amgen's Elliott Levy As Chair
www.finanznachrichten.de - September 14 at 8:30 AM
finance.yahoo.com logoNovartis' BLA for Biosimilar of Rituxan Accepted by the FDA
finance.yahoo.com - September 13 at 7:19 AM
finance.yahoo.com logoNovartis' BLA for Biosimilar of Rituxan Accepted by the FDA
finance.yahoo.com - September 13 at 7:19 AM
finance.yahoo.com logoRoche's Ophthalmology Drug Fails to Meet Primary Endpoint
finance.yahoo.com - September 12 at 7:18 AM
finance.yahoo.com logoNovartis posts a win, Roche a flop in skin cancer trials
finance.yahoo.com - September 11 at 1:17 AM
finanznachrichten.de logoNovartis: New Data Confirm Lucentis Efficacy And Durability Vs Aflibercept
www.finanznachrichten.de - September 10 at 5:08 AM
finance.yahoo.com logoLilly takes on Pfizer, Novartis with new breast cancer drug data
finance.yahoo.com - September 10 at 5:08 AM
finance.yahoo.com logoNovartis Sees Relative Strength Rating Improve To 75
finance.yahoo.com - September 9 at 6:49 AM
finance.yahoo.com logo[$$] Investors Chronicle: Redrow, Oxford BioMedica, Halfords
finance.yahoo.com - September 9 at 6:49 AM
americanbankingnews.com logoFinancial Contrast: Aralez Pharmaceuticals (ARLZ) vs. Novartis AG (NVS)
www.americanbankingnews.com - September 8 at 10:28 PM

Social

Chart

Novartis AG (NVS) Chart for Monday, October, 16, 2017

This page was last updated on 10/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.